Advanced Infusion Systems Market Size, Share, Growth, Trends, and Global Industry Analysis: By Product Type (Elastomeric Infusion Systems, Volumetric Infusion Systems, Disposable Infusion Systems, Patient Controlled Analgesia Pumps, Syringe Infusion Systems, Ambulatory Infusion Systems, and Implantable Infusion Systems), By Pumping Channel (Single Channel Infusion Pumps and Multiple Channel Infusion Pumps), By Application (Diabetes, Asthma, Chemotherapy, Pain Management, Clinical Nutrition and Others), By End User (Hospitals, Clinics, Home Care, Ambulatory Surgical Centres and Others), and Region Forecast 2019-2030

Advanced Infusion Systems Market size was valued at US$ 8,626.32 million in 2023 and is poised to grow at a CAGR of 8.4% from 2024 to 2030 due to the increasing global prevalence of chronic diseases.  An increase in the prevalence and incidence of chronic diseases such as cancer, diabetes, etc. is the key factor driving the global market growth. In addition, technological developments in advanced infusion systems which reduce the risks, increase in safety, bioavailability, and therapeutic effectiveness of drugs, and increase healthcare expenditure are the factors expected to fuel the global market over the forecast period. Similarly, increasing use of advanced infusion products in home care owing to favorable reimbursements, visual monitoring, mobility of the system, continuous infusion for multiple medications at the same time, and patient safety are a few factors that fuel the market over the forecast period.

However, a lack of awareness of using advanced infusion systems is expected to hinder the growth of the global market. Apart from this, product recalls, possible medication errors associated with an infusion pump, and strict regulations for product approval are also some key factors that might hamper the growth of the global market over the forecast period. Infusion systems are used to administer drugs or fluids in solution form to patients' blood circulatory systems in a systemic, controlled, and precise manner. The various routes to administer the drug into the patient's circulatory system including intravenous, subcutaneous, epidural, and arterial infusions are preferred based on the treatment requirement. Infusion systems were highly used for medical purposes but, owing to the increase in mortality rates with infusion systems, companies focused on the advanced infusion systems.

Advanced infusion systems have found extensive acceptance and usage across various areas of disease management. Advanced infused systems are widely used because of their dependable, ergonomic design and easy-to-use features. Advanced infusion systems are extensively used in a wide range of application areas including diabetes, oncology, enteral feeding, pain management, and general infusion. The advantage of advanced infusion systems is helping doctors to program and calculate dose delivery rates more efficiently, enabling them to provide better patient care.

Advanced Infusion Systems Market Key Developments

• Jan 2024: Dublin-Ireland-based healthcare technology leader, Medtronic plc announced CE Mark approval for the MiniMed™ 780G system with Simplera Sync, a new disposable, all-in-one continuous glucose monitor system that eliminates fingersticks and overtape. With a redefined user experience, Simplera Sync offers a very easy, two-step insertion process and is half the size of previous Medtronic sensors.         
• April 2024: Baxter International Inc, an innovative leader in infusion therapies and technologies, announced that the U.S. Food and Drug Administration has issued 510(k) clearance to its Novum IQ large volume infusion pump (LVP) with Dose IQ Safety Software. The Novum IQ Infusion Platform, with its components being Baxter's syringe infusion pump (SYR) along with Dose IQ Safety Software, powered by the IQ Enterprise Connectivity Suite, enables clinicians to use a single integrated system in a number of patient care settings with the addition of LVP modality.   
• July 2023: BD, Becton, Dickinson and Company- BD is a leading global medical technology company, announced the updated BD Alaris™ Infusion System has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA), allowing remediation and return to full commercial activities for the most comprehensive infusion system available in the United States.